Thumbnail Image
Publication

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent, M
; 
Baumert, B
; 
Erridge, S
; 
Vogelbaum, M
; 
Nowak, A
; 
Sanson, M
; 
Brandes, A
; 
Clement, P
; 
Baurain, J
; 
Mason, W
... show 10 more
Citations
Altmetric:
Abstract
The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-co-deleted anaplastic gliomas.
Authors
van den Bent, M
Baumert, B
Erridge, S
Vogelbaum, M
Nowak, A
Sanson, M
Brandes, A
Clement, P
Baurain, J
Mason, W
Wheeler, H
Chinot, O
Gill, S
Griffin, M
Brachman, D
Taal, W
Rudà, R
Weller, M
McBain, Catherine A
Reijneveld, J
Enting, R
Weber, D
Lesimple, T
Clenton, S
Gijtenbeek, A
Pascoe, S
Herrlinger, U
Hau, P
Dhermain, F
van Heuvel, I
Stupp, R
Aldape, K
Jenkins, R
Dubbink, H
Dinjens, W
Wesseling, P
Nuyens, S
Golfinopoulos, V
Gorlia, T
Wick, W
Kros, J
Affiliation
Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands
Description
Date
2017-08-08
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. 2017 Lancet
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/620551
Embedded videos